Completed
Intro
Class Central Classrooms beta
YouTube playlists curated by Class Central.
Classroom Contents
Mapping Pre-Cancer to Predict Oesophageal Cancer - Stanford Radiology CEDSS 2022
Automatically move to the next video in the Classroom when playback concludes
- 1 Intro
- 2 TODAY'S CEDSS
- 3 Introducing oesophageal cancer adenocarcino increasing incidence and poor outcomes
- 4 Early detection in oesophageal cancer
- 5 Link between mutational processes in ageing and cancer - focus on pre-cancer
- 6 Predicting progression in Barrett's: Molecular drivers from benign to malignant
- 7 Treatments for oesophageal cancer
- 8 Curative therapy for dysplasia and early car
- 9 Is Barrett's always the precursor lesion?
- 10 Molecular phenotyping suggests gastric origin and malignant transition via Barrett's
- 11 Identifying at risk group for oesophagea adenocarcinoma
- 12 Risk factors and yield of screening
- 13 Device and Assay considerations
- 14 Pan-cancer cell free DNA tests
- 15 Breath biopsy and volatile analysis
- 16 Non-endoscopic device + liquid methylation a
- 17 Sample processing for Cytosponge
- 18 TFF3 a Barrett's (intestinal metaplasia) biomarker
- 19 Manual pathology review aided by TFF3 bion
- 20 Machine learning applied to Cytosponge sa
- 21 Correlation with TFF3 count and segment le
- 22 Clinical trials for Cytosponge screenir
- 23 Primary Endpoint Results from BEST3 trial
- 24 Clinical evidence base for Cytosponge-TFF3
- 25 Monitoring Barrett's patients for dysplasia: Clinical standard surveillance protocol
- 26 Relationship p53 and Barrett's dysplasia
- 27 Timing of events in Barrett's progression
- 28 P53 immunohistochemistry as adjunct to dysplasia diagnosis
- 29 Identifying Cytosponge biomarkers for dysp
- 30 Decision Tree for Cytosponge Surveilla
- 31 Dysplasia yield across risk groups retrospe
- 32 Prospective surveillance case-studies
- 33 Biomarkers beyond p53 and atypia: DNA copy number and progression status
- 34 Can altered DNA copy number (aneuploidy) add V
- 35 Potential to add copy number for Barrett's surveillance using Cytosponge
- 36 Summary
- 37 Funding Acknowledgments
